- Zhaoke Ophthalmology has entered a memorandum of agreement with French CDMO FAREVA to serve as a trusted manufacturing partner in China.
- The deal supports Zhaoke’s global expansion strategy and leverages its Nansha-based manufacturing facility.
Zhaoke Ophthalmology Limited has signed a memorandum of agreement (MOA) with France-based FAREVA Group, a contract manufacturing organisation serving pharmaceutical, beauty, and industrial markets. Under the agreement, Zhaoke becomes the recommended partner for FAREVA customers seeking pharmaceutical manufacturing solutions in China.
The partnership aims to align FAREVA’s global customer base with Zhaoke’s domestic manufacturing strengths, particularly at its state-of-the-art facility in Nansha, Guangzhou. The agreement positions Zhaoke as a key player in contract manufacturing for ophthalmic treatments and beyond.
The announcement forms part of Zhaoke’s broader international strategy. The company intends to expand its global footprint by forming alliances that connect its R&D and production capabilities with global markets.
Commenting on the partnership, Dr Li Xiaoyi (Benjamin), Chairman, Executive Director and CEO of Zhaoke Ophthalmology, said: “We are honoured that both our R&D and world-class manufacturing capabilities have been recognized by FAREVA, further validating our global standards.”
